Li Zheng, Yin Dong-Feng, Wang Wei, Zhang Xin-Wei, Zhou Li-Jiang, Yang Jun
Graduate School, Liaoning University of Traditional Chinese Medicine, Shenyang 110847, Liaoning Province, China.
Oncology Department, The Affiliated Hospital of Liaoning University of Traditional Chinese Medicine, Shenyang 110032, Liaoning Province, China.
World J Clin Cases. 2021 Nov 16;9(32):9869-9877. doi: 10.12998/wjcc.v9.i32.9869.
At present, colorectal cancer is routinely treated with adjuvant radiotherapy and chemotherapy postoperatively. The adverse effects (AEs) of chemotherapy usually interrupt the treatment of chemotherapy. Traditional Chinese medicine (TCM) has demonstrated great potential in improving patients' clinical symptoms, regulating the immune function, improving the life quality, and reducing the AEs of chemotherapy.
To observe the clinical efficacy of Yiqi Jianpi anti-cancer prescription combined with chemotherapy in patients with colorectal cancer after operation.
Data from patients diagnosed with colorectal cancer between January 2019 and February 2021 were collected from Liaoning Cancer Hospital and Institute and the Second Affiliated Hospital of Liaoning University of Traditional Chinese Medicine. Patients receiving the chemotherapy regimen of capecitabine plus oxaliplatin (CAPOX) after radical resection of colorectal cancer were prospectively collected and randomly divided into an experimental group and a control group. The experimental group was given Yiqi Jianpi anti-cancer prescription combined with the CAPOX regimen, while the control group was given the CAPOX regimen alone. After six cycles of chemotherapy, the scores of TCM symptoms, Karnofsky performance scale (KPS) score, levels of T-cell subsets, and AEs after chemotherapy of the two groups were compared.
A total of 70 patients were randomly divided into either an experimental group ( = 35, no dropout) or a control group ( = 33, with 2 dropouts). Compared with the control group, the experimental group improved significantly ( < 0.05) in scores of TCM symptoms, KPS score, levels of T-cell subsets, and AEs of chemotherapy.
Yiqi Jianpi anti-cancer prescription can effectively improve spleen deficiency, regulate the immune function, and alleviate the AEs of chemotherapy, so as to improve the life quality of patients with good therapeutic effects and application prospect in clinical practice.
目前，结直肠癌术后常规采用辅助放疗和化疗。化疗的不良反应通常会中断化疗治疗。中医在改善患者临床症状、调节免疫功能、提高生活质量以及减轻化疗不良反应方面已显示出巨大潜力。
观察益气健脾抗癌方联合化疗对结直肠癌术后患者的临床疗效。
收集2019年1月至2021年2月在辽宁省肿瘤医院和辽宁中医药大学附属第二医院确诊为结直肠癌的患者资料。前瞻性收集接受结直肠癌根治性切除术后采用卡培他滨加奥沙利铂（CAPOX）化疗方案的患者，并随机分为实验组和对照组。实验组给予益气健脾抗癌方联合CAPOX方案，而对照组仅给予CAPOX方案。化疗六个周期后，比较两组的中医症状评分、卡氏功能状态量表（KPS）评分、T细胞亚群水平以及化疗后的不良反应。
共70例患者被随机分为实验组（n = 35，无脱落）或对照组（n = 33，2例脱落）。与对照组相比，实验组在中医症状评分、KPS评分、T细胞亚群水平以及化疗不良反应方面均有显著改善（P < 0.05）。
益气健脾抗癌方能有效改善脾虚，调节免疫功能，减轻化疗不良反应，从而提高患者生活质量，具有良好的治疗效果和临床应用前景。
